BRIEF published on 05/14/2024 at 22:26, 1 year 11 months ago Bausch Health annonce des mises à jour sur le litige Norwich XIFAXAN et une nouvelle soumission à la FDA XIFAXAN Bausch Santé Contentieux Des Brevets Norwich Pharmaceutique Soumission À La FDA
BRIEF published on 05/14/2024 at 22:20, 1 year 11 months ago Sonnet BioTherapeutics Announces Fiscal Year 2024 Q2 Results and Business Updates Financial Results Clinical Trials Oncology Biopharmaceuticals Sonnet BioTherapeutics
BRIEF published on 05/14/2024 at 22:20, 1 year 11 months ago Sonnet BioTherapeutics annonce ses résultats du deuxième trimestre de l'exercice 2024 et des mises à jour sur ses activités Résultats Financiers Essais Cliniques Oncologie Sonnet BioTherapeutics Produits Biopharmaceutiques
BRIEF published on 05/14/2024 at 22:20, 1 year 11 months ago NANOBIOTIX Lance une Étude de Phase 2 sur le Traitement du Cancer du Poumon avec FDA Approval FDA Étude De Phase 2 NANOBIOTIX Cancer Du Poumon NBTXR3
BRIEF published on 05/14/2024 at 22:20, 1 year 11 months ago NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
BRIEF published on 05/14/2024 at 22:15, 1 year 11 months ago GENFIT Announces Q1 2024 Financials and Projects Cash Runway into Late 2025 Cash Position Clinical Trials Revenue Decline Biopharmaceutical Industry GENFIT Financial Results
BRIEF published on 05/14/2024 at 22:15, 1 year 11 months ago GENFIT annonce ses résultats financiers du premier trimestre 2024 et dispose d'une trésorerie disponible jusqu'à fin 2025 Industrie Biopharmaceutique Essais Cliniques Baisse Des Revenus Résultats Financiers De GENFIT Situation De Trésorerie
BRIEF published on 05/14/2024 at 22:10, 1 year 11 months ago Protagonist Therapeutics to Present New Rusfertide Study Data at EHA Congress 2024 Clinical Study Protagonist Therapeutics Rusfertide Polycythemia Vera EHA Congress 2024
BRIEF published on 05/14/2024 at 22:10, 1 year 11 months ago Protagonist Therapeutics présentera de nouvelles données de l'étude Rusfertide au congrès de l'EHA 2024 Étude Clinique Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Congrès EHA 2024
BRIEF published on 05/14/2024 at 22:10, 1 year 11 months ago Vicinity Motor Corp. Reports Strong First Quarter 2024 Financial Results Financial Results Revenue Growth Electric Vehicles Market Expansion Vicinity Motor Corp
Published on 04/29/2026 at 15:15, 4 hours 5 minutes ago Reeflex Solutions Inc. Announces Filing of Q2 2026 Financial Results
Published on 04/29/2026 at 15:10, 4 hours 10 minutes ago Karbon-X Introduces Corporate Emissions Calculator as Pressure to Quantify Carbon Exposure Accelerates
Published on 04/29/2026 at 14:31, 4 hours 49 minutes ago Worksport (NASDAQ:WKSP) Secures Tri-State Distribution, Books Initial Orders, Projected to be 7-Figure + Annual Account
Published on 04/29/2026 at 14:30, 4 hours 50 minutes ago Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Published on 04/29/2026 at 19:00, 20 minutes ago SIX Exchange Regulation approves extension of exemption from specific disclosure requirements
Published on 04/29/2026 at 18:30, 50 minutes ago IEVA GROUP: MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
Published on 04/29/2026 at 18:30, 50 minutes ago EQS-Adhoc: Talanx achieves quarterly result of EUR 774 million
Published on 04/29/2026 at 18:05, 1 hour 15 minutes ago VerifyVASP acquires Sygna, consolidating the global Travel Rule network
Published on 04/29/2026 at 18:15, 1 hour 5 minutes ago GUILLEMOT CORPORATION | MISE A DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL INCLUANT LE RAPPORT FINANCIER ANNUEL 2025
Published on 04/29/2026 at 18:15, 1 hour 5 minutes ago GUILLEMOT CORPORATION | AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE 2025 ANNUAL FINANCIAL REPORT
Published on 04/29/2026 at 18:10, 1 hour 10 minutes ago Amemdment of the resolution n8 submitted to the AGM of 30 April 2026
